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This knowledge-based activity is targeted for all pharmacists and 
is acceptable for 1.0 hour (0.1 CEU) of continuing education credit. 
This course requires completion of the program evaluation and at 
least a 70 percent grade on the program assessment questions. 
ACPE Universal Activity Number (UAN): 0048-0000-11-025-H04-P 
Objectives: 
After completion of this program, the reader should be able to: 
1. Describe the most common toxicity concerns in pediatric patients. 
2. List the medications that pose substantial morbidity and mortality 
risk in the pediatric patient with the consumption of one to two doses. 
3. Name the clinical implications of common medications resulting in 
poisonings. 
4. Describe the role of the pharmacist in poisoning treatment recom-
mendations and prevention. 
Abstract 
Pediatric poisoning remains a common and preventable occur-
rence in the United States. Every year, prescription and over-the-
counter medications account for a significant portion of docu-
mented poison exposures. Frequent causes of overdose in children 
include improper medication storage and caregiver or physician 
dosing error. As easily accessible medication experts, pharmacists 
have an opportunity to counsel patients in an effort to decrease 
these preventable poisoning cases. Because children frequently 
ingest products prescribed for adult use, pharmacists should relay 
safety considerations to all patients, regardless of age. This article 
provides a general review of toxicity concerns, discusses clinical 
implications of common medications resulting in poisonings and 
of those that are lethal in one or two doses, and describes the role 
of the pharmacist in poisoning treatment recommendations and 
prevention. 
Background 
Young children's tendency to place objects in their mouths, interest in 
exploring their environment, lack of judgment, and their inability to read 
make them more likely to be victims of unintentional poisoning. Accord-
ing to the 2009 Annual Report of the American Association of Poison 
Control Center (AAPCC), approximately 52 percent of poison exposures 
occurred in children five years of age and younger.1 Among the top 10 
substances children were exposed to, many were common over-the-
counter products such as analgesics, topical preparations, and cold 
and cough preparations. An overdose of these products may occur from 
repeated doses or administration errors.2 Repeated doses can occur 
when more than one caregiver administers a dose of medication to a 
child or a child administers more than one dose of a medication to himself. 
Administration errors are more likely to occur when dosing instructions are 
misinterpreted, the weight of the child is unknown, or units on a dosing cup 
or syringe are confused. 
Medication errors that result in toxicity present an opportunity for pharma-
cist involvement to target specific products for additional patient counsel-
ing and respond to questions from concerned caregivers about potential 
poisonings. Pharmacists may face questions regarding both highly toxic 
medications and those that may be less toxic but more commonly result 
in pediatric concern. Therefore, it is important that pharmacists be aware 
and knowledgeable of both. The objective of this article is to provide a 
general review of toxicity concerns, discuss clinical implications of common 
medications resulting in poisonings and those that are lethal in one or 
two doses, and describe the role of the pharmacist in poisoning treatment 
recommendations and prevention. 
Lethal in 1-2 Doses 
Diphenoxylate-Atropine (Lomotil®) 
The opioid antidiarrheal agent diphenoxylate-atropine is believed to cause 
serious toxicity in the pediatric population through ingestion of only one or 
two pills.3 Each tablet contains a combination of 2.5 mg diphenoxylate and 
0.025 mg of atropine. This product is not recommended in children under 
the age of four. Children above age four have a recommended daily dose 
of 0.3 to 0.4 mg/kg/24 hours in four divided doses, while the adult dose is 5 
mg four times daily. All pharmacokinetic studies have been done in adults, 
so there is no data available to fully understand its action in children. Seri-
ous toxicity due to ingestion of diphenoxylate-atropine is manifested as 
respiratory depression, aspiration pneumonia, cerebral edema and death. 
Clinical features of toxicity display both anticholinergic and opioid features 
due to the combination of the two drug classes. Patients may display tachy-
cardia, flushing, urinary retention, miosis, lethargy and even coma. Thom-
as, Pauze, and Love reviewed cases of reported toxicity in the pediatric 
population due to exposure to diphenoxylate-atropine.3 Children ingested 
multiple tablets or were given repeat doses, which resulted in opioid side 
effects such as lethargy and respiratory depression. The recommendation 
is to rapidly initiate gut decontamination to avoid significant morbidity and 
mortality. At this time, there is no known minimal toxic dose; the lowest re-
ported toxic dose was ingestion of half of a tablet by a six-month-old infant. 
Additionally, there is not a correlation to the quantity of drug ingested to 
the severity of symptoms of toxicity. It is recommended that patients with 
overdose or suspected toxicity be placed on a cardiac monitor, with fre-
quent monitoring of vital signs and mental status changes. Since one of the 
properties of the drug is to delay GI emptying, decontamination needs to be 
employed either through administration of activated charcoal or via gastric 
lavage. It is not advised to administer an emetic. If the patient displays 
symptoms of altered mental status or respiratory depression, naloxone 
should be administered. For cases of significant ingestion of diphenoxylate-
atropine, an observation period of 12-24 hours is recommended as well as 
admittance to a pediatric intensive care unit. 
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Transdermaf Patches 
Use of transdermal medication administration in the pediatric popula-
tion has increased in popularity and can allow for effective dosing; 
however, there are also significant toxicity risks due to the thinness and 
increased perfusion of their skin.4 In order to allow the drug to reach 
therapeutic levels and an adequate drug gradient, a 20-fold excess of 
drug is included in transdermal drug delivery systems. Due to the high 
drug content, there is a significant amount of drug remaining in patches 
after their removal. The Texas Poison Central Network (TPCN) con-
ducted a retrospective study of transdermal drug exposures from 2002 
to 2006 in the pediatric population under age 12. There were 110 cases 
that fell within the criteria, and the average age of children exposed 
was 11.5 months. Nearly half of the exposures were via the oral route, 
in which the child was found either sucking or chewing on a medicated 
patch. Only 13 percent of the cases involved actual oral ingestion of 
the patch. The second most common route was via dermal application 
of patches. There were very few cases involving an actual therapeutic 
error. Camphor or menthol patches and other over-the-counter prepara-
tions such as salicylate or nicotine patches were most often involved in 
poisoning reports. Methylphenidate, often prescribed for the treatment 
of ADHD in children, as well as clonidine, estrogen hormone, lidocaine, 
nitroglycerin and opioid patches were also responsible for reports to the 
TPCN. About 40 percent of the exposures did not result in any adverse 
effects; however, one death was attributed to opioid toxicity. Six percent 
of the children exposed inappropriately to transdermal patches were 
hospitalized as a result of their exposure. Since 50 percent of the calls 
were related to pediatric exposure to adult-based prescription medica-
tions, proper storage and disposal education is necessary for patients 
who employ this dosage form. 
Calcium Channel Blockers 
Calcium channel blockers (CCB) are one of the most frequently pre-
scribed classes of cardiac medications, making them highly accessible 
to a curious child.5 According to a report by the American Association 
of Poison Control Centers, CCB and beta blocker ingestions are listed 
in the top 10 causes of toxin-related deaths in children under the age of 
six.5 Morbidity and mortality associated with CCB toxicity are a result of 
conduction delays and blocks, decreased myocardial contractility, and 
loss of systemic vascular smooth muscle tone. As a result of negative 
inotropic and chronotropic effects, verapamil and diltiazem overdoses 
typically present with bradycardia, heart block, AV conduction distur-
bances and myocardial dysfunction. The most common side effect with 
overdose of any CCB is hypotension. Hypoperfusion can cause a range 
of effects from mild orthostasis and nausea to cerebral ischemic events 
and renal failure. Despite the fact that CCBs have not been approved for 
use in the pediatric population for the treatment of hypertension, several 
medications, such as nifedipine and verapamil, are frequently prescribed 
for hypertensive children. Ranniger and Roche conducted a retrospec-
tive review of cases involving pediatric toxicity related to CCB exposure.5 
One of the most commonly ingested CCBs was nifedipine, with 18 case 
reports of toxic or fatal outcomes in toddlers. Half of the cases resulted 
in death, with three of them occurring after only ingesting one or two 
pills. Second was verapamil, with five of the 12 cases resulting in a fatal 
outcome. Altered mental status was the most common clinical manifes-
tation resulting from verapamil toxicity. In all of the cases reported, there 
were varying doses and dosage forms (immediate vs. sustained-release) 
ingested. Due to this variance, it is difficult to identify a toxic dose. Both 
extended- and sustained-release formulations can prove to be highly 
toxic due to the potential of the child sucking or chewing a pill, causing an 
increased dose to be released immediately. Also, the toxic dose often over-
lapped with nontoxic doses, further complicating toxic range identification. 
Gastric lavage is not an ideal treatment as there is risk of increasing vagal 
tone in cases where bradycardia or heart block are displayed. Current rec-
ommendations suggest that activated charcoal be administered within two 
hours of CCB ingestion, with monitoring for six hours for regular-release 
products and up to 24 hours for sustained-release medications. 
Camphor 
Camphor is an aromatic terpene ketone used topically as an analgesic, an-
tipruritic and antitussive agent. Camphor is present in topical preparations 
like Vicks VapoRub® and BenGay®. At doses as little as 500 mg, camphor 
has been shown to cause death; just 4 teaspoons of Vicks VapoRub could 
be fatal. Early clinical manifestations of toxic exposure are gastrointestinal 
upset and a general sensation of warmth. Symptoms can progress rapidly 
from a phase of CNS hyperactivity, including excitement, restlessness, 
delirium and seizures, to a phase of CNS depression with coma and re-
spiratory depression. There is no specific antidote for camphor poisoning; 
however, supportive treatment involving seizure control and airway man-
agement is employed. Referral to the emergency room is recommended for 
patients ingesting 500 mg or more of camphor.6•7 
Saficylate 
Salicylate can be found in aspirin, Pepto-Bismol® and oil of wintergreen 
and is thought to be toxic at levels of 150 mg/kg. Oil of wintergreen, a 
common food flavoring, has the highest salicylate content. One teaspoon-
ful contains four times the dose of salicylate thought to be toxic in a 1 O kg 
child. Almost 90 baby aspirin would be needed to reach the same toxic 
level. Additionally, the half-life of salicylate in children increases from two 
to four hours at therapeutic levels to 15-29 hours at toxic levels. Signs 
of toxicity are nausea, vomiting, diaphoresis, tinnitus, agitation, delirium, 
hallucinations and lethargy. Salicylate ingestion stimulates the respiratory 
center in the brainstem, causing hyperventilation and hyperpnea. High lev-
els of ingested salicylates may cause pulmonary edema, cerebral edema, 
coma and death. Classic laboratory findings for salicylate toxicity include 
an acid-base disturbance present as an anion gap metabolic acidosis with 
respiratory alkalosis. Management of salicylate poisoning should begin 
with determination of serum salicylate concentrations. Treatment options 
consist of supportive care, gastric decontamination, urine alkalinization to 
enhance salicylate elimination, and hemodialysis.6•7 
Suffonyfureas 
Sulfonylureas such as glyburide and glipizide are oral hypoglycemic 
agents commonly used in the management of type 2 diabetes. In 2009, the 
AAPCC documented 922 exposures to sulfonylureas in children less than 
five. 1 Literature suggests ingestion of only one or two tablets in a toddler 
has the potential to cause hypoglycemia, neurologic sequelae and, poten-
tially, death.8 Signs of hypoglycemia in young children include weakness, 
fussiness, dizziness, change in behavior, seizure, decreased appetite and 
focal neurologic deficit. Little and Boniface reviewed available literature 
on pediatric sulfonylurea exposures and formulated recommendation 
guidelines.8 Because children younger than six have small glycogen stores, 
recommendations for suspected sulfonylurea ingestions currently favor 
hospitalization and eight hours of observation with hourly serum glucose 
monitoring, even when asymptomatic. The observation period should be 
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extended if glipizide XL consumption is suspected due to its delayed 
peak time. If hypoglycemia is detected, blood glucose level determina-
tion and stabilization is imperative. Appropriate treatment in symptomatic 
patients includes IV administration of a dextrose bolus and continuation 
of monitoring for several hours after the infusion. A continuous infusion 
of glucose may be required and should be considered on a case-to-case 
basis. In patients who are refractory to IV glucose administration, treat-
ment with octreotide and diazoxide may be considered. Although contro-
versial, activated charcoal may be given within one hour of ingestion.8 
Common Prescription Medications of Concern 
Montelukast 
Montelukast has been approved for use in the pediatric population for 
chronic treatment of asthma and allergic rhinitis.9 For patients six to 
14 years old, the daily dose is 5 mg, and for children under six years 
old, it is 4 mg. There have been few adverse effects with ingestion of 
montelukast, typically headache, influenza, abdominal pain, cough and 
dizziness. A review of reports from the AAPCC did not cite any deaths 
associated with ingestion of montelukast. A TPCN retrospective study 
identified pediatric montelukast ingestion in patients ranging from age 
zero to five years old that were reported to their center between 2000 
and 2005. During the study time period, there were a total of 3,698 
reports. The number of tablets ingested ranged from <1to134. Almost 
all of the cases reported had an outcome that could be classified as no 
effect, and there were no major adverse events or deaths. Most cases 
could be treated at home, with only a small number of patients needing 
to seek medical attention. The suggested home treatment is decontami-
nation, which can be accomplished by dilution and food. In the medi-
cal setting, activated charcoal followed by a cathartic was employed. 
Observations made from this study indicate that pediatric ingestions of 
montelukast up to 536 mg or 33.71 mg/kg are not likely to result in any 
major adverse clinical events. 
Atomoxetine 
Atomoxetine hydrochloride is indicated for use in pediatric patients 
with attention-deficit/hyperactivity disorder (ADHD).10 Dosing initi-
ates at 0.5 mg/kg with titration up to the target dose of 1.2-1.4 mg/kg/ 
day. The recommended daily dose has relatively low adverse effects, 
including dyspepsia, nausea, vomiting, rash, decreased appetite and 
weight loss. Stojanovski et al. conducted a retrospective study of calls 
received in 2004 at a regional poison control center in Ohio, with the 
goal of establishing adverse drug reactions and toxicities in the pediatric 
population. The mean dose reported was 85 ± 59.6 mg, and only 33 
percent of the cases reported adverse drug reactions: agitation, head-
ache, erythema, rash, elevated blood pressure and heart rate, emesis 
and nausea, and lethargy. Over half of these cases could be observed 
at home. Those requiring medical treatment received either activated 
charcoal or activated charcoal and a cathartic. All of the cases identified 
had resolution of adverse effects within 24 hours. The most severe case 
identified a 15-year-old boy who had ingested 1,200 mg (22 mg/kg) and 
experienced both seizures and cardiac conduction delays. His treatment 
was aggressive and included activated charcoal, intravenous fluids, 
diazepam, and phenytoin. Because it is difficult to identify children at low 
risk of developing adverse reactions, it is recommended all atomoxetine 
exposures be referred to the emergency department for observation, 
monitoring of vital signs, and possibly gastric decontamination. 
Angiotensin Converting Enzyme (ACE) Inhibitors 
The angiotensin converting enzyme (ACE) inhibitor lisinopril has been found 
to be both safe and effective as a treatment for hypertension in children age 
six to 16; however, safety in younger populations has not been adequately 
evaluated.11 Previous study findings have indicated that ingestion of <1 mg/ 
kg is able to be managed at home. The TPCN conducted a retrospective 
study using data collected on lisinopril ingestions from 1998-2005 in patients 
under age six in order to propose triage guidelines for pediatric ingestion 
of lisinopril. The maximum dose was 32.8 mg or 2.6 mg/kg, but typically 
the child had ingested only one tablet. Ingestion was usually a result of 
the child accessing someone else's medication, a parent giving the child 
the wrong medication, or a pharmacy filling error. In 95.7 percent of the 
cases reviewed, there were no serious outcomes. Adverse clinical effects 
observed included hypotension, vomiting and drowsiness. Decontamination 
with food and dilution was most often used, and activated charcoal was 
employed when serious outcomes were found. More severe cases required 
the administration of IV fluids and vasopressors when managing hypoten-
sion. The triage guidelines indicate that for doses s 4 mg/kg, s 80 mg, or s 5 
tablets, home management is adequate.11 
Analgesics 
The most frequently reported drug exposures reported to poison control 
centers (PCC) are analgesics.12 Since acetaminophen is the antipyretic-
analgesic most commonly used in children, it is one of the most commonly 
ingested. Poison control centers received a quarter of a million calls from 
2000 to 2003 regarding acetaminophen poisoning. Angalakuditi, Coley, and 
Krenzelok conducted a retrospective review of acetaminophen exposures 
in children less than 18 years of age, occurring between Oct. 31, 2000, and 
Oct. 31, 2003, that were managed by an MPCC-certified regional poison 
control center (RPCC). There were 473 pediatric exposures identified, 75.9 
percent of which occurred in children younger than six years of age. The 
mean dose of acetaminophen reported was 3,685 ± 6,985 mg. Hepatotoxic-
ity risk is associated with acute acetaminophen ingestions of 150-200 mg/ 
kg; mortality is rare. Since acetaminophen poisoning is a preventable injury, 
health care professionals have a critical role in patient education. Parents 
should be educated on medications they are giving their children, specifi-
cally nonprescription drugs, since they are more likely to rely on caregiver 
interpretation of directions and be administered to young children. A study 
by Snyder reported that 88 percent of parents who were administering 
nonprescription medications to their children were not adequately educated 
on the medication itself. In a mock exercise, only 40 percent of caregivers 
could correctly state the dosage of acetaminophen for their child, and only 
43 percent could measure the correct dose. 
Dosing Errors 
Research suggests that dosing errors are the most frequent type of thera-
peutic error in the pediatric population, largely due to the increased calcu-
lations involved when prescribing, dosing and administering medications 
to children.13- 15 Pediatric patients may have rapidly changing body weights 
and changing pharmacokinetic parameters that require dose recalculation. 
Other sources of error are off-label use of medications and the inability 
of young children to communicate with their provider. Most institutional 
dosing errors are commonly related to antibiotic dosing. 13•16·17 Error in an-
tibiotic dosing has been shown to occur in neonates less than seven days 
old when doses are not modified with their maturation and changing body 
weight. Errors also have been associated with the administration of fluids 
and electrolytes as well as dilution of intravenous medications. 16 
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The most common type of dosing error is the tenfold dosing error. 
The 2009 Annual AAPCC Report stated that more than 50 percent of 
all tenfold dosing errors occurred in children under age six.1 A tenfold 
dosing error results in the administration of a dose 10 times higher or 
lower than the intended dose. Errors may be caused by miscalculations, 
transcription errors, the use of incorrect units, placing a terminal zero to 
the right of a decimal point (12.0 rather than 12), or not placing a zero to 
the left of a decimal point (.8 instead of 0.8). Tenfold dosing errors have 
higher incidence of fatal outcomes because they tend to be associated 
with a higher chance of toxicity or lack of efficacy than other types of 
errors. 14 
How Pharmacists Can Help 
As a pharmacist, performing medication therapy intervention (MTI) can 
help identify prescribing errors. A two-week study was conducted in the 
community pharmacy setting in which pharmacists in five states submitted 
an MTI form to document pharmacist actions taken to resolve electronic 
prescribing problems. 18 The overall intervention rate was found to be 3.8 
percent, with most interventions being to supplement missing information 
and correct inappropriate dosing. Most pharmacists resolved the problem 
by contacting the prescriber, and over half of all interventions ended in a 
change to the prescription bet ore dispensing to the patient. 
Pharmacists can help prevent accidental poisoning of children by educat-
ing parents and caregivers about ways to reduce therapeutic errors (Table 
1 ), proper medication storage out of the reach of children, and the differ-
ence between child-resistant and child-proof containers. Child-resistant 
does not mean child-proof. 19 Child-resistant packaging is designed to be 
easy for adults to open, but significan~y difficult for children under five 
years of age to open within a reasonable period of time. Eighty-five percent 
of children under the age of five should not be able to open the package 
in a five-minute time period. Pharmacists should promote the use of child-
resistant caps to patients that have children or have children visit them. For 
patients that find the caps difficult to open, the pharmacist can demonstrate 
their use. In states that allow a blanket request for non-child-resistant caps, 
a pharmacist may want to periodically ensure that patients who opt out of 
this safety measure understand the increased risk of child poisoning that 
may occur. 
Table 1: Caregiver strategies for reducing therapeutic errors2 
·Avoid distractions when administering medications 
• Double-check all medications and doses prior fo administration 
with another person if possible 
• Communicate with other medication administrators 
• Record when a dose is given 
• Advise other caregiver that dose was given 
• Have only one caregiver administer all doses 
• Have specific storage for 
• Each person's medication 
• Internal and non-internal medications 
• Medications taken at different times of day 
• Make sure measuring devices are familiar and have clear markings 
• Only keep one strength of a medication if possible 
• Clearly label the dosage instructions and routes of administration 
Conclusion 
In general, pediatric poisoning is a common and preventable occurrence. 
Counseling often only occurs on pediatric medications, but common and 
often more serious ingestions also involve products rarely used in or con-
traindicated in children; therefore, pharmacists should relay safety consid-
erations to all patients, regardless of age. As easily accessible medication 
experts, pharmacists should intervene in an effort to decrease preventable 
poisoning cases in children. 
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Assessment Questions 
1. All of the following statements regarding salicylate toxicity are true 
except: 
a. In children, the half-life of salicylate is independent of the 
amount of salicylate ingested. 
b. Salicylate toxicity presents as an anion gap metabolic acidosis 
with respiratory alkalosis. 
c. Salicylate stimulates the respiratory center in the brainstem and 
can cause hyperventilation. 
d. Pepto-Bismol, aspirin, and oil of wintergreen all contain salicylate. 
2. Dosing errors in the pediatric population occur when: 
a. There is failure to recalculate doses for maturing patients with 
changing body weights 
b. A tenfold dosing error is made 
c. Intravenous medications are not properly dilute 
d. All of the above 
3. What is the suggested treatment for a child who has ingested monte-
lukast and is being observed at home? 
a. Nothing 
b. Decontamination with food and fluids 
c. Administration of a cathartic 
d. None of the above 
4. What is (are) the recommendation(s) for atomoxetine exposure? 
a. Emergency department observation 
b. Vital sign monitoring 
c. Gastric decontamination 
d. All of the above 
5. Which Angiotensin Converting Enzyme (ACE) Inhibitor has been ap-





6. What is the most common route of unintended exposure of transder-





7. Drug exposures of which class are most commonly reported to poison 
control centers? 
a. Analgesics 
b. ACE Inhibitors 
c. Beta-Blockers 
d. HMG-CoA Ruductase Inhibitors 
8. The smallest reported toxic dose of diphenoxylate-atropine is: 
a.% tablet 
b. 1 tablet 
c. 2 tablets 
d. 4 tablets 
9. Which Calcium Channel Blockers (CCBs) are the most likely to be 




d. A and C 
e. Band C 
10. Appropriate management strategies for suspected sulfonylurea 
exposures in children less than 6 include: 
a. Home observation for asymptomatic patients 
b. Glucose bolus administration in symptomatic patients 
c. Octreotide use in glucose resistant patients 
d. Band C 
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